Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Change in Cash (2016 - 2025)

Tvardi Therapeutics' Change in Cash history spans 13 years, with the latest figure at -$684000.0 for Q4 2025.

  • On a quarterly basis, Change in Cash fell 103.08% to -$684000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.9 million, a 225.13% decrease, with the full-year FY2025 number at -$10.9 million, down 225.13% from a year prior.
  • Change in Cash hit -$684000.0 in Q4 2025 for Tvardi Therapeutics, down from $770000.0 in the prior quarter.
  • Over the last five years, Change in Cash for TVRD hit a ceiling of $25.4 million in Q2 2022 and a floor of -$16.3 million in Q1 2023.
  • Historically, Change in Cash has averaged $970350.0 across 5 years, with a median of -$1.2 million in 2024.
  • The widest YoY moves for Change in Cash: up 13880.43% in 2022, down 696.34% in 2022.
  • Tracing TVRD's Change in Cash over 5 years: stood at -$9.5 million in 2021, then skyrocketed by 319.49% to $20.9 million in 2022, then plummeted by 153.02% to -$11.1 million in 2023, then soared by 299.78% to $22.2 million in 2024, then crashed by 103.08% to -$684000.0 in 2025.
  • Business Quant data shows Change in Cash for TVRD at -$684000.0 in Q4 2025, $770000.0 in Q3 2025, and -$7.3 million in Q2 2025.